Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-TIMI 50 trial

This publication has 17 references indexed in Scilit:

• Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
  New England Journal of Medicine, 2007
• Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial
  JACC, 2007
• One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis
  JAMA, 2007
• Protease-Activated Receptors in Cardiovascular Diseases
  Circulation, 2006
• Thrombin Receptor (Protease Activated Receptor-1) Antagonists as Potent Antithrombotic Agents with Strong Antiplatelet Effects
  Journal of Medicinal Chemistry, 2006
• Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
  New England Journal of Medicine, 2006
• Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial
  The Lancet, 2005
• Addition of Clopidogrel to Aspirin and Fibrinolytic Therapy for Myocardial Infarction with ST-Segment Elevation
  New England Journal of Medicine, 2005
• Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
  BMJ, 2002
• Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
  New England Journal of Medicine, 2001